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Abstract
For high-risk soft tissue sarcomas (HR-STS) of adults,
new treatment strategies are needed to improve out-
come with regard to local control and overall survival.
Therefore, systemic chemotherapy has been integrated
either after (adjuvant) or before (neoadjuvant) optimal
local treatment by surgery and radiotherapy in HR-STS.
The combination with regional hyperthermia as a new
treatment strategy seems to open a new therapeutic win-
dow.
Copyright © 2003 S. Karger AG, Basel
High-Risk Soft Tissue Sarcomas
Soft tissue sarcomas (STS) represent a heterogeneous
group of relatively rare malignancies with a wide spec-
trum in terms of histologic type and prognosis [1]. In the
last decade the use of limb-sparing surgery and postopera-
tive irradiation has become standard practice in the man-
agement of resectable extremity STS with 5-year rates of
local control similar to those reported with radical resec-
tion or amputation [2, 3]. However, the anatomic location
(e.g. retroperitoneal, visceral, RP/V) and invasiveness of
STS often prevent resection with adequate margins [4],
and the toxicity of radiotherapy limits the use of poten-
tially therapeutic doses with negative impact on local
control [5]. In addition, unfavorable prognosis of STS
is determined by high-grade histology, large tumor size
(65 cm) and deep localization [6]. While median overall
survival (OS) for patients with extremity lesions is 33
months, patients with high-grade tumors of the retroperi-
toneum were reported to have an even worse prognosis
with a median OS between 9 and 20 months despite surgi-
cal resection [7]. Recently it was shown that RP/V site is
an additional poor prognosticator independent of other
factors like tumor size, grade and recurrence [8]. Typically
the majority of patients with RP/V tumors frequently die
with local disease without evidence of distant metastasis
at the time of death. Further adjuvant treatment modali-
ties like early postoperative intraperitoneal Adriamycin,
high-dose adjuvant radiotherapy with protecting silicone
implants or IORT were explored in small patient series.
As a reflection of these obstacles, the strategy of sys-
temic chemotherapy has been integrated in the multidis-
ciplinary approach either after (adjuvant) or before and
after (neoadjuvant) locally curative treatment, mainly in
order to eradicate distant micrometastases thought to be
present at the time of diagnosis. Once inoperative meta-
static disease with progression becomes measurable, the
intention of systemic chemotherapy remains only pallia-
tive.
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Rationale of Regional Hyperthermia Combined
with Systemic Chemotherapy
Within the last 15 years, regional hyperthermia (RHT)
as a new treatment modality has entered clinical trials [9].
The results of phase II studies in pretreated and locally
advanced patients with STS are encouraging and justify
further testing in randomized studies as first-line treat-
ment for well-defined risk groups [10].
The rationale for the combination of cytotoxic drugs
with hyperthermia in the treatment of high-risk STS (HR-
STS) is based on experimental evidence that heat expo-
sure increases the killing of tumor cells by direct thermal
cytotoxicity and is able to sensitize perfused tumor tissue
towards chemotherapy in a synergistic manner [11]. In
addition, recent results indicate that heat-shock proteins
induced in tumor cells under hyperthermic stress are able
to elicit specific T- and NK-cell immune responses [12].
Hyperthermia in combination with radiotherapy as
neoadjuvant treatment for HR-STS patients has already
shown to impact positively on local tumor control, where-
as it did not seem to influence the rate of distant metas-
tases or survival [13].
In an effort to improve both local tumor control and
micrometastases, a multimodality treatment strategy in-
cluding RHT combined with chemotherapy seemed at-
tractive to be explored in HR-STS. The objective of this
report is to determine response rate and survival parame-
ters for patients with HR-STS at different sites after
neoadjuvant thermochemotherapy.
Neoadjuvant Chemotherapy Alone
Preoperative chemotherapy (chemotherapy delivered
before local therapy) has some advantages over postoper-
ative treatment, because the presence of evaluable tumor
allows the determination of chemotherapy sensitivity
clinically as well as pathologically, and valuable prognos-
tic information may be obtained. The primary tumor may
also be downstaged, and some lesions that were technical-
ly unresectable may become more amenable to surgical
intervention. In addition, drug delivery to the primary
tumor may be improved because surgery and radiation
therapy have not yet been delivered and the tumor’s vas-
cular supply remains undisturbed.
The EORTC has completed the first randomized trial
on neoadjuvant chemotherapy in patients with resectable
STS of the extremities, head, neck and trunk. Only high-
risk patients were eligible, based on tumor size (18 cm) or
intermediate/high histological grade (mitotic count 63/
10 high-power fields). Three courses of chemotherapy
(doxorubicin 50 mg/m2 + ifosfamide 5 g/m2) were admin-
istered before definitive surgery and radiotherapy. Che-
motherapy had to start within 6 weeks of biopsy or at an
attempt at definitive surgery. Patients in the control arm
proceeded to immediate surgery and postoperative radio-
therapy. 150 patients were entered into the study and 134
were eligible, 67 in each arm [14]. This trial was closed
after completion of phase II since accrual was insufficient
to justify expanding the study into the scheduled phase III
study. Objective response rate to preoperative chemother-
apy in 49 patients assessable for response was 29%. At a
median follow-up of 7.3 years, the 5-year DFS was 52%
(control arm) and 56% (chemotherapy arm), respectively
(p = 0.35).
Several phase II studies of neoadjuvant chemotherapy
have been carried out in patients with bulky STS accord-
ing to risk factors (tumor size, grade, inadequate surgery,
local recurrence). It appeared that some patients benefit
from chemotherapy because formerly inoperable cases
were rendered operable [15–17].
Clinical Results of RHT Combined with
Neoadjuvant Chemotherapy
In 1986, at the Klinikum Grosshadern Medical Center
(KGMC), we initiated a phase II study for patients with
advanced chemoresistant STS combining second-line
chemotherapy with RHT [18]. These patients had re-
lapsed after prior surgery and radiation, and had not
responded to previously given doxorubicin-based chemo-
therapy alone. A drug combination of ifosfamide + etopo-
side (VP-16) was used, combined with RHT as a second-
line treatment. The local response rate was 37%. Besides
long-term tumor control in a subgroup of patients, the
analysis of tumor temperatures (e.g. T20, T50, T90)
achieved using an electromagnetic deep regional-heating
device (BSD system) showed significantly higher temper-
ature parameters in responders than in non-responders.
The results have been confirmed in the extended trial
including 65 patients with chemo-pretreated sarcomas
[19].
Thereafter, two additional consecutive phase II studies
at the KGMC were performed in HR-STS but these
patients had not received prior chemotherapy (chemo-
naive patients). In the first study (RHT-91 protocol), 59
patients received 4 cycles of EIA consisting of etoposide,
ifosfamide and doxorubicin combined with concurrent
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RHT. The RHT was applied using the BSD system and
the aim was to achieve a maximum tumor temperature of
642°C for a period of 60 min. Following this treatment,
those patients whose tumor was judged to be resectable
underwent surgery. If the tumor showed signs of response,
4 additional cycles of combined chemotherapy and hyper-
thermia were given. All patients not preirradiated also
received external beam radiotherapy. Treatment-related
toxicity was acceptable. Median survival was 52 months
and the 5-year survival rate was 49% (95% CI 36–61%).
The data are in favor of the patients responding to EIA
combined with hyperthermia [20].
In the second study (RHT-95 protocol), a similar high-
risk patient group (54 patients) received the same treat-
ment as in the RHT-91 protocol with the exception that
the patients did not receive hyperthermia but chemother-
apy alone after surgery. This study showed an inferior
local failure-free survival (LFFS) rate compared with the
RHT-91 protocol, but no difference in overall survival
[21]. Thus, postsurgical hyperthermia may be critical for
local control.
From 1991 to 1997, a total of 58 patients with HR-STS
at RP/V sites were prospectively treated with 4 cycles of
etoposide, ifosfamide and doxorubicin combined with
RHT followed by surgery, adjuvant chemotherapy and
radiation. Objective response rate assessable in 40 pa-
tients was 13% (5 partial responses). Including minor
responses (n = 8), the radiographic response rate was 33%.
Pathologic response rate assessable in 26 patients after
surgical resection was 42%. Median OS was 31 months.
At a median observation time of 74 months, 5-year proba-
bility of LFFS, distant metastasis-free survival, event-free
survival and OS were 25, 51, 20 and 32%, respectively.
Averaged minimum temperatuers (Tmin) and time-aver-
aged temperatures achieved in 50% (T50) and 90% (T90)
of all measured tumor sites differed significantly between
responders and non-responders (Tmin: 39.3 vs. 38.0°C,
p = 0.002; T50: 40.9 vs. 40.3°C, p = 0.038; T90: 40.1 vs.
39.3°C, p = 0.017). At 5-year follow-up, probability of
LFFS (59 vs. 0%; p ! 0.001) and OS (60 vs. 10%; p !
0.001) was significantly in favor of patients responding to
neoadjuvant thermochemotherapy [22]. It is important to
note that besides inclusion of unfavorable anatomic tu-
mor sites and recurrent STS, the study protocol allowed
inclusion of patients who had tumors that were not ade-
quately resectable before entering the study. This argues
for a high burden of patients with unfavorable prognosis
in our study in contrast to other neoadjuvant treatment
protocols where only patients were included who were
judged to have resectable tumors before the start of
neoadjuvant chemotherapy [15]. The fact that R0 resec-
tion was achieved in a proportion of patients after neoad-
juvant treatment supports the idea of a tumor downstag-
ing. Moreover, it was demonstrated that previously re-
sected patients who had only microscopic tumor left at the
start of protocol treatment had a significantly higher prob-
ability of local relapse in comparison with patients whose
tumor was resected after neoadjuvant thermochemother-
apy.
The EORTC Soft Tissue and Bone Sarcoma Group
(STBSG) is further testing this multimodal concept as a
first-line treatment of HR-STS in adults in a multicenter
prospective phase III trial (EORTC 62961/ESHO RHT-
95), as an Intergroup study with the European Society of
Hyperthermic Oncology (ESHO) [23]. Patients meeting
all of the eligibility criteria at first presentation (tumor
size 65 cm, grade II or grade III, extracompartmental) or
after inadequate surgery (resections with microscopic/
macroscopic residual tumor) are entered in this protocol
with the intention of improving local tumor control and
early prevention of systemic metastasis. According to the
inclusion criteria defined above, the majority of patients
with HR-STS recruited for this multimodality treatment
protocol cannot be controlled by standard procedures. All
eligible patients will be randomized to receive either 4
cycles of EIA (etoposide 250 mg/m2 + ifosfamide 6 g/m2 +
doxorubicin 50 mg/m2) within 12 weeks (chemotherapy
arm) or the same EIA regimen combined with RHT (RHT
arm). The patients will then receive optimal local treat-
ment using adequate surgery immediately followed by
radiotherapy. After the completion of radiotherapy an
additional 4 cycles of EIA chemotherapy alone or in com-
bination with RHT will be given. The application of RHT
with external annular phased array applicators (60–
100 MHz) results in a selective temperature elevation
(range 40–44°C) within the tumor and the directly adja-
cent tissue. The EIA regimen of the neoadjuvant protocol
combines conventional doses of the most active single
agents (doxorubicin + ifosfamide) in STS with etoposide
being added prior to RHT on day 1 and 4 of each cycle.
This combination of systemic EIA chemotherapy and
RHT has been shown to be effective in HR-STS and
allows an adequate conservative surgical approach after 4
EIA/RHT cycles in responding patients for whom radical
resection without mutilation (e.g. hemipelvectomy, am-
putation) was formerly considered impossible [20].
At present more than 180 patients have been recruited
for this Intergroup study. For the final analysis, about 170
patients are required in each treatment arm.
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Conclusions
A short description of the background, the special
design, and the rationale of phase II and an ongoing phase
III protocol for patients with HR-STS is given including
RHT combined with systemic chemotherapy. Clinical
advances in the treatment of STS are often hampered by
the difficulty in accrual of patients for prospective clinical
trials. The intention of this review is to emphasize that
collaboration among European institutions and among
the individual oncologist is the only basis that can provide
the answer for the definitive role of new strategies such as
RHT in the treatment of HR-STS.
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